Integer’s (ITGR) “Equal Weight” Rating Reiterated at Wells Fargo & Company

Wells Fargo & Company restated their equal weight rating on shares of Integer (NYSE:ITGR) in a report published on Friday morning, MarketBeat reports. The brokerage currently has a $80.00 price target on the medical equipment provider’s stock, down from their previous price target of $132.00.

ITGR has been the subject of several other reports. Raymond James Financial lowered their price target on Integer from $150.00 to $143.00 and set an “outperform” rating for the company in a report on Friday, July 25th. Truist Financial lowered their price target on Integer from $137.00 to $121.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. Wall Street Zen upgraded Integer from a “hold” rating to a “buy” rating in a report on Saturday, August 30th. Citigroup downgraded Integer from a “buy” rating to a “neutral” rating and lowered their price target for the company from $140.00 to $77.00 in a report on Thursday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Integer in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, Integer currently has a consensus rating of “Hold” and an average target price of $97.75.

Integer Trading Down 1.3%

ITGR stock opened at $72.94 on Friday. The company has a market cap of $2.56 billion, a price-to-earnings ratio of 30.52, a PEG ratio of 0.57 and a beta of 0.97. The company has a quick ratio of 2.45, a current ratio of 3.71 and a debt-to-equity ratio of 0.70. The business has a fifty day simple moving average of $103.61 and a 200-day simple moving average of $112.45. Integer has a 52 week low of $66.50 and a 52 week high of $146.36.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, October 23rd. The medical equipment provider reported $1.79 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.11. The company had revenue of $467.69 million for the quarter, compared to the consensus estimate of $466.45 million. Integer had a return on equity of 12.84% and a net margin of 4.75%.The company’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the business posted $1.43 EPS. Integer has set its FY 2025 guidance at 6.290-6.430 EPS. On average, equities research analysts expect that Integer will post 6.01 EPS for the current year.

Hedge Funds Weigh In On Integer

Hedge funds have recently bought and sold shares of the company. Intech Investment Management LLC grew its stake in Integer by 92.8% in the first quarter. Intech Investment Management LLC now owns 22,682 shares of the medical equipment provider’s stock worth $2,677,000 after purchasing an additional 10,915 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in Integer in the first quarter valued at approximately $916,000. Russell Investments Group Ltd. boosted its stake in Integer by 14.7% in the first quarter. Russell Investments Group Ltd. now owns 6,749 shares of the medical equipment provider’s stock valued at $796,000 after acquiring an additional 863 shares during the period. KLP Kapitalforvaltning AS boosted its stake in Integer by 6.1% in the second quarter. KLP Kapitalforvaltning AS now owns 7,000 shares of the medical equipment provider’s stock valued at $861,000 after acquiring an additional 400 shares during the period. Finally, Aberdeen Group plc boosted its stake in Integer by 38.5% in the second quarter. Aberdeen Group plc now owns 319,229 shares of the medical equipment provider’s stock valued at $39,256,000 after acquiring an additional 88,784 shares during the period. 99.29% of the stock is currently owned by institutional investors and hedge funds.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.